The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Prescription of Long-Acting Opioids and Mortality in Patients With Chronic Noncancer Pain
Open accessAbstract
IMPORTANCE: Long-acting opioids increase the risk of unintentional overdose deaths but also may increase mortality from cardiorespiratory and other causes. OBJECTIVE: To compare all-cause mortality for patients with chronic noncancer pain who were prescribed either long-acting opioids or alternative medications for moderate to severe chronic pain. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study between 1999 and 2012 of Tennessee Medicaid patients with chronic noncancer pain and no evidence of palliative or end-of-life care. EXPOSURES: Propensity score-matched new episodes of prescribed therapy for long-acting opioids or either analgesic anticonvulsants or low-dose cyclic antidepressants (control medications). MAIN OUTCOMES AND MEASURES: Total and cause-specific mortality as determined from death certificates. Adjusted hazard ratios (HRs) and risk differences (difference in incidence of death) were calculated for long-acting opioid therapy vs control medication. RESULTS: There were 22,912 new episodes of prescribed therapy for both long-acting opioids and control medications (mean [SD] age, 48 [11] years; 60% women). The long-acting opioid group was followed up for a mean 176 days and had 185 deaths and the control treatment group was followed up for a mean 128 days and had 87 deaths. The HR for total mortality was 1.64 (95% CI, 1.26-2.12) with a risk difference of 68.5 excess deaths (95% CI, 28.2-120.7) per 10,000 person-years. Increased risk was due to out-of-hospital deaths (154 long-acting opioid, 60 control deaths; HR, 1.90; 95% CI, 1.40-2.58; risk difference, 67.1; 95% CI, 30.1-117.3) excess deaths per 10,000 person-years. For out-of-hospital deaths other than unintentional overdose (120 long-acting opioid, 53 control deaths), the HR was 1.72 (95% CI, 1.24-2.39) with a risk difference of 47.4 excess deaths (95% CI, 15.7-91.4) per 10,000 person-years. The HR for cardiovascular deaths (79 long-acting opioid, 36 control deaths) was 1.65 (95% CI, 1.10-2.46) with a risk difference of 28.9 excess deaths (95% CI, 4.6-65.3) per 10,000 person-years. The HR during the first 30 days of therapy (53 long-acting opioid, 13 control deaths) was 4.16 (95% CI, 2.27-7.63) with a risk difference of 200 excess deaths (95% CI, 80-420) per 10,000 person-years. CONCLUSIONS AND RELEVANCE: Prescription of long-acting opioids for chronic noncancer pain, compared with anticonvulsants or cyclic antidepressants, was associated with a significantly increased risk of all-cause mortality, including deaths from causes other than overdose, with a modest absolute risk difference. These findings should be considered when evaluating harms and benefits of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has been found that the use of long-term opioid treatment increases the risk of death due to unintentional overdose and cardiorespiratory problems [5].”
From Pain acceptance creates an emotional context that protects against the misuse of prescription opioids: A study in a sample of patients with chronic noncancer pain (2021) · cites this paper as [5]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · JAMA · doi:10.1001/jama.2016.1464 · Cited by 5,161
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980
Survival analysis using sas®: a practical guide
Allison, P. D. (1995) · International Linear Collider · Cited by 3,570
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
Chou, R., Turner, J. A., Devine, E. B., Hansen, R. N., Sullivan, S. D., Blazina, I., Dana, T., Bougatsos, C., & Deyo, R. A. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2559 · Cited by 1,606
Association Between Opioid Prescribing Patterns and Opioid Overdose-Related Deaths
Bohnert, A. S. B. (2011) · JAMA · doi:10.1001/jama.2011.370 · Cited by 1,509
Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008.
Paulozzi, L. J., Jones, C. M., Mack, K. A., & Rudd, R. A. (2011) · PubMed · Cited by 1,350
Opioid Prescriptions for Chronic Pain and Overdose
Dunn, K. M., Saunders, K. W., Rutter, C. M., Banta‐Green, C. J., Merrill, J. O., Sullivan, M. D., Weisner, C. M., Silverberg, M. J., Campbell, C. I., Psaty, B. M., et al. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-2-201001190-00006 · Cited by 1,265
Opioid Therapy for Chronic Pain
Ballantyne, J. C., & Mao, J. (2003) · New England Journal of Medicine · doi:10.1056/nejmra025411 · Cited by 960
A Flood of Opioids, a Rising Tide of Deaths
Okie, S. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1011512 · Cited by 832
Gabapentin for chronic neuropathic pain and fibromyalgia in adults
Moore, A., Wiffen, P. J., Derry, S., & McQuay, H. J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007938.pub2 · Cited by 729
Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008.
(2011) · PubMed · Cited by 640
Chou, R., & Huffman, L. H. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-7-200710020-00008 · Cited by 583
Park, T. W., Saitz, R., Ganoczy, D., Ilgen, M. A., & Bohnert, A. S. B. (2015) · BMJ · doi:10.1136/bmj.h2698 · Cited by 579
CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · MMWR Recommendations and Reports · doi:10.15585/mmwr.rr6501e1er · Cited by 549
Dhalla, I. A., Mamdani, M., Sivilotti, M. L. A., Kopp, A., Qureshi, O., & Juurlink, D. N. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.090784 · Cited by 439
The Comparative Safety of Analgesics in Older Adults With Arthritis
Solomon, D. H. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.391 · Cited by 409
Menendez, M. E., Ring, D., & Bateman, B. T. (2015) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-015-4173-5 · Cited by 340
USE OF MEDICAID DATA FOR PHARMACOEPIDEMIOLOGY
Ray, W. A., & Griffin, M. R. (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115198 · Cited by 316
Gabapentin for chronic neuropathic pain and fibromyalgia in adults
Moore, R. A., Wiffen, P. J., Derry, S., & Rice, A. S. C. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007938.pub3 · Cited by 297
Amitriptyline for neuropathic pain and fibromyalgia in adults
Moore, R. A., Derry, S., Aldington, D., Cole, P., & Wiffen, P. J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008242.pub2 · Cited by 293
Cyclic antidepressants and the risk of sudden cardiac death
Ray, W. A., Meredith, S. K., Thapa, P. B., Hall, K., & Murray, K. T. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.019 · Cited by 274
Miller, M., Barber, C. W., Leatherman, S. M., Fonda, J. R., Hermos, J. A., Cho, K., & GAGNON, D. R. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.8071 · Cited by 256
Carragee, E. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp042054 · Cited by 218
Chronic Opioid Use and Central Sleep Apnea
Correa, D., Farney, R. J., Chung, F. F., Prasad, A., Lam, D., & Wong, J. (2015) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000000672 · Cited by 200
McCarberg, B. H., & Barkin, R. L. (2001) · American Journal of Therapeutics · doi:10.1097/00045391-200105000-00006 · Cited by 187
Arbogast, P. G., & Ray, W. A. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwr143 · Cited by 138
Use of disease risk scores in pharmacoepidemiologic studies
Arbogast, P. G., & Ray, W. A. (2008) · Statistical Methods in Medical Research · doi:10.1177/0962280208092347 · Cited by 135
A Primer on Propensity Score Analysis
Shadish, W. R., & Steiner, P. M. (2010) · Newborn and Infant Nursing Reviews · doi:10.1053/j.nainr.2009.12.010 · Cited by 121
Overdose Deaths Involving Prescription Opioids Among Medicaid Enrollees--Washington, 2004-2007
(2009) · PsycEXTRA Dataset · doi:10.1037/e552162010-002 · Cited by 117
Population-Based Studies of Adverse Drug Effects
Ray, W. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmp038145 · Cited by 100
Out-of-Hospital Mortality Among Patients Receiving Methadone for Noncancer Pain
Ray, W. A., Chung, C. P., Murray, K. T., Cooper, W. O., Hall, K., & Stein, C. M. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.6294 · Cited by 91
Immunosuppressive Effects of Opioids—Clinical Relevance
Brack, A., Rittner, H. L., & Stein, C. (2011) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-011-9290-7 · Cited by 77
Opioid Medication and Sleep-disordered Breathing
Yue, H. J., & Guilleminault, C. (2010) · Medical Clinics of North America · doi:10.1016/j.mcna.2010.02.007 · Cited by 75
METHODOLOGICAL ISSUES IN EVALUATING EXPANDED MEDICAID COVERAGE FOR PREGNANT WOMEN
Piper, J. M., Ray, W. A., Griffin, M. R., Fought, R. L., DAUGHTERY, J. R., & Mitchel, E. F. (1990) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115692 · Cited by 72
Time Scale and Adjusted Survival Curves for Marginal Structural Cox Models
Westreich, D. J., Cole, S. R., Tien, P. C., Chmiel, J. S., Kingsley, L., Funk, M. J., Anastos, K., & Jacobson, L. P. (2010) · American Journal of Epidemiology · doi:10.1093/aje/kwp418 · Cited by 65
Adjustment for Multiple Cardiovascular Risk Factors Using a Summary Risk Score
Arbogast, P. G., Kaltenbach, L. A., Ding, H., & Ray, W. A. (2008) · Epidemiology · doi:10.1097/ede.0b013e31815be000 · Cited by 58
Opioids, Sleep, and Sleep-Disordered Breathing
Zutler, M., & Holty, J.-E. C. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796197070 · Cited by 51
Mansukhani, M. P., Wang, S., & Somers, V. K. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00285.2015 · Cited by 35
Evidence, regulation and ‘rational’ prescribing: the case of gabapentin for neuropathic pain
Ghinea, N., Lipworth, W. L., & Kerridge, I. (2014) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12223 · Cited by 25
Performance of time-dependent propensity scores: a pharmacoepidemiology case study
Ray, W. A., Liu, Q., & Shepherd, B. E. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3727 · Cited by 22
Amitriptyline for neuropathic pain and fibromyalgia in adults
Moore, R. A., Derry, S., Wiffen, P. J., & McQuay, H. J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008242 · Cited by 19
The Epidemic of Opioid Use: Implications for the Sleep Physician
Lee‐Iannotti, J. K., & Parish, J. M. (2014) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.3790 · Cited by 11
Reimbursement of analgesics for chronic pain
Pedersen, L., Hansen, A. B., Svendsen, K., Skurtveit, S. O., Borchgrevink, P. C., & Fredheim, O. M. S. (2012) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.11.1214 · Cited by 6
Cited by
Sorted by citations
Colloca, L., Ludman, T., Bouhassira, D., Baron, R., Dickenson, A. H., Yarnitsky, D., Freeman, R. L., Truini, A., Attal, N., Finnerup, N. B., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.2 · Cited by 2,253
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7103a1 · Cited by 1,886
Krebs, E. E., Gravely, A., Nugent, S., Jensen, A. C., DeRonne, B., Goldsmith, E. S., Kroenke, K., Bair, M. J., & Noorbaloochi, S. (2018) · JAMA · doi:10.1001/jama.2018.0899 · Cited by 983
Opioids for Chronic Noncancer Pain
Busse, J. W., Wang, L., Kamaleldin, M., Craigie, S., Riva, J. J., Montoya, L., Mulla, S. M., Lopes, L. C., Vogel, N., Chen, E., et al. (2018) · JAMA · doi:10.1001/jama.2018.18472 · Cited by 766
Epidemiology of cardiovascular disease in young individuals
Andersson, C., & Vasan, R. S. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.154 · Cited by 760
Metadata
- Authors
- Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M.
- Affiliations
- Vanderbilt University (US)
- Corresponding author
- Ray, Wayne A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-06-14
- Volume
- 315
- Issue
- 22
- Pages
- 2415
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC5030814
- OpenAlex
- W2429408914
- Cited by
- 369
- References
- 44
- Citations by year
- 2026: 10 · 2025: 21 · 2024: 23 · 2023: 25 · 2022: 29 · 2021: 41 · 2020: 57 · 2019: 48 · 2018: 56 · 2017: 41 · 2016: 15
- FWCI
- 52.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Rheumatology Research Foundation
- National Heart, Lung, and Blood Institute (R01HL081707)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23AR064768)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- long-acting opioids, chronic non-cancer pain, all-cause mortality, out-of-hospital death, opioid overdose, Medicaid patients, opioid prescribing, cardiovascular mortality, respiratory mortality
- MeSH terms
- Analgesics, Opioid, Anticonvulsants, Antidepressive Agents, Cardiovascular Diseases, Cause of Death, Female, Fentanyl, Humans, Male, Methadone, Middle Aged, Morphine, Oxycodone, Drug Prescriptions, Retrospective Studies, Risk, Proportional Hazards Models, Propensity Score, Chronic Pain, Drug Overdose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review